Cannabinoids Improve Gastrointestinal Symptoms in a Parenteral Nutrition-Dependent Patient With Chronic Intestinal Pseudo-Obstruction.

Détails

ID Serval
serval:BIB_709CE5C4723C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Cannabinoids Improve Gastrointestinal Symptoms in a Parenteral Nutrition-Dependent Patient With Chronic Intestinal Pseudo-Obstruction.
Périodique
JPEN. Journal of parenteral and enteral nutrition
Auteur⸱e⸱s
Zemrani B., Lambe C., Goulet O.
ISSN
1941-2444 (Electronic)
ISSN-L
0148-6071
Statut éditorial
Publié
Date de publication
02/2021
Peer-reviewed
Oui
Volume
45
Numéro
2
Pages
427-429
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: ppublish
Résumé
Chronic intestinal pseudo-obstruction (CIPO) is a rare and challenging cause of pediatric intestinal failure, requiring long-term parenteral nutrition in most cases. Despite optimal management, some patients experience chronic abdominal pain and recurrent obstructive episodes with a major impact on their quality of life. Cannabinoids have been successfully used in some conditions. However, their use in CIPO has never been reported in the literature. We report a case of successful use of medicinal cannabinoids in a patient with CIPO, resulting in a significant reduction of abdominal pain, vomiting, and subocclusive episodes and increased appetite and weight, without major adverse events. Although further observations are required to consolidate these findings, this case may be helpful for other patients suffering from the same condition.
Mots-clé
Cannabinoids, Child, Chronic Disease, Humans, Intestinal Pseudo-Obstruction/complications, Intestinal Pseudo-Obstruction/therapy, Parenteral Nutrition, Total, Quality of Life, cannabinoids, children, intestinal failure, parenteral nutrition
Pubmed
Web of science
Création de la notice
02/04/2020 16:56
Dernière modification de la notice
20/02/2024 8:17
Données d'usage